Artelo Biosciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARTL Nasdaq 2830 artelobio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artelo Biosciences, Inc.

Artelo Biosciences Announces Reverse Stock Split - Aug 27th, 2026 6:00 am
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - Aug 20th, 2026 6:52 am
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies - Aug 17th, 2026 6:52 am
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results - Aug 13th, 2026 6:00 am
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition - Jul 22nd, 2026 6:39 am
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions - Jul 16th, 2026 6:48 am
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 - Jul 14th, 2026 6:47 am
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy - Jul 13th, 2026 7:02 am
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury - Jul 1st, 2026 6:42 am
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 - Jun 30th, 2026 6:57 am
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 - Jun 29th, 2026 6:45 am
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success - Jun 10th, 2026 5:38 am
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results - May 14th, 2026 2:05 pm
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development - Apr 28th, 2026 6:25 am
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile - Apr 20th, 2026 5:50 am
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements - Apr 7th, 2026 5:50 am
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Mar 30th, 2026 2:46 pm
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Mar 27th, 2026 8:40 am
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments - Mar 25th, 2026 2:05 pm